Wednesday, June 29, 2011

The Devil and a Dingbat: Sid Harth

  1. Web
  2. Images
  3. Videos
  4. Maps
  5. News
  6. Shopping
  7. Gmail
  8. more
Example: "CSCO" or "Google"

Eli Lilly & Co.

(Public, NYSE:LLY)   Watch this stock
Find more results for LLY
Dow Jones 12,188.69 1.21%
S&P 500 1,296.67 0.00%
Healthcare 1.28%
LLY 37.35 0.00%










37.35 
0.00 (0.00%)
Pre-market: 37.79 +0.44 (1.18%) 
Jun 29, 9:01AM EDT 
NYSE real-time data - Disclaimer 
Currency in USD
  1. Range     -
  2. 52 week 32.82 - 39.40
  3. Open     -
  4. Vol / Avg. 600.00/6.92M
  5. Mkt cap 43.24B
  6. P/E 8.48
  7. Div/yield 0.49/5.25
  8. EPS 4.40
  9. Shares 1.16B
  10. Beta 0.77
Jul 21, 2011
Q2 2011 Earnings Conference Call - 9:00AM EDT - Add to calendar
Jul 21, 2011
Q2 2011 Earnings Release Add to calendar
Jun 30, 2011
Investment Community Meeting - 8:30AM EDT - Add to calendar
Jun 1, 2011
And Co at Sanford C. Bernstein & Co. Strategic Decisions Conference
Apr 18, 2011
Q1 2011 Earnings Release
Apr 18, 2011
Q1 2011 Earnings Conference Call
More events from DailyFinance »

Key stats and ratios


 Q1 (Mar '11) 2010
Net profit margin 18.08% 21.97%
Operating margin 21.82% 28.28%
EBITD margin - 33.77%
Return on average assets 13.51% 17.34%
Return on average equity 32.14% 46.20%
Employees 38,165 -
Carbon Disclosure Rating - 58/100

Address

Lilly Corporate Center Indianapolis, IN 46285 United States - Map +1-317-2762000 (Phone) +1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
About Company - Wikipedia
Discussion Group - Google Finance
Compare: 
more »
               
Settings | Plot feeds | Technicals | Link to chart icon. Link to this view
Volume delayed by 15 mins.

Eli Lilly & Co. discussed on blogs

Description

Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 125 countries. s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. In the United States, Eli Lilly and Company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. During the year ended December 31, 2010, it acquired Alnara Pharmaceuticals, Inc. and Avid Radiopharmaceuticals, Inc. On May 28, 2010, it acquired the European marketing rights to several animal health product lines divested by Pfizer Inc., as part of its acquisition of Wyeth, Inc. 

Officers and directors

John C. Lechleiter Ph.D.
Chairman of the Board, President, Chief Executive Officer
Derica W. Rice
Chief Financial Officer, Executive Vice President - Global Services
Frank M. Deane Ph.D.
President - Manufacturing Operations
Bryce D. Carmine
Executive Vice President and President - Lilly Bio-Medicines
Jan M. Lundberg Ph.D.
Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Anne Nobles
Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Robert A. Armitage
Senior Vice President, General Counsel
Stephen F. Fry
Senior Vice President - Human Resources and Diversity
Enrique A. Conterno
Senior Vice President and President - Lilly Diabetes
Susan Mahony Ph.D.
Senior Vice President and President - Lilly Oncology
 

Wednesday, June 29, 2011

Business Day


 LAST CHANGE VOLUME
At close 06/28/2011 $37.35 +0.52 +1.41% 600.00
PRE-MARKET 9:01 AM ET $37.79 +0.44 +1.18%

Eli Lilly and Company

LLY: NYSE; Healthcare/Pharmaceuticals - Diversified
OTHER EXCHANGES: Mexico, London, More »
 
Updated: Oct. 1, 2010 Eli Lilly and Company is a global pharmaceutical company based in Indianapolis, Ind. Founded in 1876,  Lilly is the world's foremost manufacturer and distributor of psychiatric medications, and was the first company to mass-produce penicillin. Long a powerhouse for drugs like Prozac, Zyprexa and Cymbalta, Lilly is looking to new drug opportunities in treating cancer and Alzheimer’s, two diseases that will become more pressing as Americans live longer. But these are challenging times for Lilly. It is losing patent protection in the next seven years on drugs that accounted for 74 percent of its sales in 2009. Lilly has also been hit by recent legal, regulatory and research disappointments, including the surprise announcement in August 2010 that a promising experimental drug treatment for Alzheimer’s was being dropped because it hurt patients’ cognitive functions more than it helped. Lilly’s patent losses are daunting: Its schizophrenia drug Zyprexa, whose sales in 2009 represented 23 percent of the company’s total, goes off patent in 2011. Cymbalta, with $3.07 billion in sales, loses patent protection in 2013. In addition, Lilly lost legal challenges this year to Gemzar, a cancer drug that sold $1.36 billion, and Strattera, a treatment for attention-deficit hyperactivity disorder that sold $609 million. Analysts point to a lack of promising products in the company’s short-term outlook. For example, Lilly has introduced only one product in the last five years, the blood thinner Effient, to sluggish early sales. It has virtually no new products to market until 2013, when it hopes to start rolling out two a year. Read More...

Company Information

Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 125 countries. s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. In the United States, Eli Lilly and Company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. During the year ended December 31, 2010, it acquired Alnara Pharmaceuticals, Inc. and Avid Radiopharmaceuticals, Inc. On May 28, 2010, it acquired the European marketing rights to several animal health product lines divested by Pfizer Inc., as part of its acquisition of Wyeth, Inc. 
Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 Phone: +1 (317) 276-2000 Fax: +1 (317) 276-3492  Web site

ARTICLES ABOUT ELI LILLY & COMPANY

Newest First | Oldest First 
Page: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next >>
This Week's Health Industry News
By REED ABELSON
It is earnings season for several major drug companies. April 18, 2011
Alzheimer’s Test, First of Its Kind, Clears Hurdle
By GINA KOLATA
A committee voted that the agency approve the first test that can show Alzheimer’s in the brain of a living person. January 21, 2011
Two Alzheimer’s Tests Show Promise for Early Diagnosis
By GINA KOLATA
Researchers report major advances on two vexing questions about Alzheimer’s: How do you know if someone who is demented has it? And how can you screen the general population for risk? January 19, 2011
Study Finds Lack of Disclosure Among Advocacy Groups
By DUFF WILSON
Using data made public by Eli Lilly, a Columbia University review shows many advocacy organizations don't disclose donors with potential conflicts. January 13, 2011
Lilly Enters Diabetes Alliance With German Drug Maker
By DUFF WILSON
Eli Lilly joins with Boehringer Ingelheim to market new drugs. January 11, 2011
PRESCRIPTIONS; Lilly Beats Estimates and Raises Full-Year Forecast
By DUFF WILSON
Eli Lilly & Co reports third-quarter profit of $1.3 billion, or $1.18 per share, up 38 percent from year-ago quarter; revenue was $5.65 billion; photo October 22, 2010
New Lab Complexes Aim at a Biotech Future for New York
By ALISON GREGOR
New York wants to attract the industry to the city, and two buildings are offering scientists the space. October 20, 2010
Rediscovering the First Miracle Drug
By ABIGAIL ZUGER, M.D.
Injectable insulin, long sought by researchers, is a blockbuster medication whose birth is almost forgotten. October 5, 2010
Patents Ending, Eli Lilly Chases New Drugs
By DUFF WILSON
The company is facing losing patent protection on drugs that accounted for 74 percent of its sales in 2009. October 1, 2010
BUSINESS BRIEFING | LEGAL; Eli Lilly Wins Court Ruling In Zyprexa Case
By BLOOMBERG NEWS
New York federal appeals court throws out ruling against Eli Lilly & Co that granted class-action status to suit claiming improper marketing of schizophrenia drug Zyprexa September 11, 2010
SEARCH 474 ARTICLES ABOUT ELI LILLY & COMPANY: 
Page: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next >>
Copyright © 2008. Quotes and other information supplied by independent providers identified on the vendor disclosures page.

Price Chart

Data delayed at least 15 minutes

Stock Snapshot

Tuesday's open $36.98
Tuesday's close $37.35
52-week range
52-week high $39.40
52-week low $32.82
Market capitalization 43.2B
Avg. volume (10-day) 6.7M
Shares outstanding 1.2B
Dividend (yield) $1.96 (5.25%)
Ex-dividend date 08/11/2011

Key Fundamentals

P/E ratio 8.5x
Earnings per share $4.40
Revenue $23.4B
Profit margin 20.82%
Return on equity 39.98%
Fundamentals are for the trailing 12 months

Quarterly Earnings

Analyst Ratings

Buy 1
Outperform 1
Hold 13
Underperform 4
Sell 3
Consensus
Hold
(As of 06/24/2011)

Executive Officers

Executive Title
John C. Lechleiter Chmn. since 2009
Derica W. Rice CFO since 2010
Frank M. Deane Corp.Exec. since 2007
Bryce D. Carmine Exec.VP since 2009
Jan M. Lundberg Exec.VP since 2010

Latest Insider Trades

06/27/2011
DEANE FRANK M
Open market or private sale of non-derivative or derivative security
Shares sold: 1,700
Share price: $36.74
Trans. value: $62,458
06/27/2011
DEANE FRANK M
Open market or private sale of non-derivative or derivative security
Shares sold: 3,300
Share price: $36.73
Trans. value: $121,209
06/20/2011
DEANE FRANK M
Open market or private sale of non-derivative or derivative security
Shares sold: 5,000
Share price: $37.38
Trans. value: $186,900

Company Events

  • On April 18, 2011, LLY announced quarterly earnings of $1.24 per share for 2011Q1, beating the consensus estimate of $1.17.

Filings

10-K 
Annual Financials
February 22, 2011
10-Q 
Quarterly Financials
October 29, 2010
10-Q 
Quarterly Financials
July 30, 2010

Peer Performance

 30-day % change 52-week % change 3-month avg. vol.
Eli Lilly and Company –2.94% +9.79% 1.6M
Patents Ending, Eli Lilly Chases New Drugs »
Achillion Pharmaceuticals Inc. +2.80% +231.90% 256.7K
Inhibitex Inc. –12.85% +42.86% 173.3K
Domain Registration Corporation –39.05% –96.57% 51.9K

Rss Feeds On Eli Lilly and Company

Subscribe to an RSS feed on this topic. What is RSS?

Times Select Content Get Alerts On Eli Lilly and Company

Receive My Alerts e-mails on topics covered on this page.
More Alerts »
  • U.S.
  • Europe
  • Asia
DOW 12,188.69 145.13 1.21%
S&P 500 1,296.67 16.57 1.29%
NASDAQ 2,729.31 41.03 1.53%

S&P 500 1,296.67 1.29%

NASDAQ 2,729.31 1.53%

STOXX 50 2,811.36 2.21%

FTSE 100 5,850.30 1.45%

DAX 7,298.48 1.79%

NIKKEI 9,797.26 1.54%

TOPIX 844.11 1.66%

HANG SENG 22,061.18 -0.00%

GOLD 1,509.10 0.59%

OIL (WTI) 93.69 0.86%

U.S. 10-YEAR 100.53 3.06%

UK 10-YEAR 103.28 3.33%

JAPAN 10-YEAR 100.74 1.12%

DOW 12,188.69 1.21%
Last Update: Jun 28
1.412%
PRICE: 37.350 USD

Eli Lilly & Co (LLY:US)

Industry: Medical-Drugs •  New York  • Currency: USD

Snapshot 
- Eli Lilly & Co (LLY)
Sponsored by

Advertisement
Summary
INTRA-DAY INTERACTIVE CHART
Change 0.520 (1.412%) Intra-Day Chart for Eli Lilly & Co (LLY:US)
Bid 37.500
Ask 37.780
Open 36.980
High 37.360
Low 36.870
Volume N.A.
52-Week Range 39.40 - 32.82
1-Yr Return 16.804%

Earnings 
- Eli Lilly & Co (LLY)

Earnings
Fundamentals
Earnings Past 12 Months 4.780 Shares (Millions) 1,157.666
Quarter Est. EPS (06/11) 1.17 Market Cap (Millions) 43,238.840
Quarter Est. EPS (09/11) 1.08 Float (Millions) 1,019.655
Year Est. EPS (12/11) 4.27 Return on Equity 46.204
Price/Earnings (Trailing) 7.814 Short Interest 28,512,297.000
Relative P/E 0.529 Last Dividend Reported 0.490 Regular Cash
Earnings Growth Rate -9.900 Dividend Yield (ttm) 5.248
Estimated P/E 8.700 Relative Dividend Yield 2.693

Interactive Chart 
- Eli Lilly & Co (LLY)

Unless indicated otherwise: intraday data is at least 15 minutes delayed; mutual fund NAVs are updated at the close of every market day; all prices are in the local currency; Time is ET.

Sponsored Links

American Express—Savings High Yield Savings Account With No Fees And Competitive Rates. PersonalSavings.AmericanExpress.com Wells Fargo Advisors Estate Planning Kit Download a free toolkit and understand the essentials of planning your estate. WellsFargoAdvisorsInfo.com
Calamos Growth Funds Find Mutual Funds that Outperform their Peers. Visit Calamos Today. www.calamos.com/growthworks 95% Payout in 1 Hour ! Its Simple, You can Make 95% Profit in less than 1 hour :Start Now ! Winoptions.com
iShares ETFs - Official Site Get Up-to-Date Holdings & Specific Fund Information for iShares ETFs. www.iShares.com Buy a link »

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
Advertisement
Advertisements
Click here to find out more!
Click here to find out more!
Advertisement
Sponsored Links

Eli Lilly and Company

From Wikipedia, the free encyclopedia
For other uses, see Eli Lilly (disambiguation).
Eli Lilly and Company
Eli Lilly and Company
Type Public
Traded as NYSE: LLY
Industry Pharmaceuticals
Founded 1876
Founder(s) Eli Lilly
Headquarters Indianapolis, Indiana, U.S.
Key people John C. Lechleiter (Chairman, President and CEO)
Products Prozac Humalog Cialis Strattera Darvocet
Revenue increase US$ 23.076 billion (2010)[1]
Operating income increase US$ 6.525 billion (2010)[1]
Net income increase US$ 5.070 billion (2010)[1]
Total assets increase US$ 31.001 billion (2010)[1]
Total equity increase US$ 12.431 billion (2010)[1]
Employees 38,350 (December 2010)[1]
Website Lilly.com
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. The company was founded in 1876 by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named. Among other specialties, Lilly was the first company to mass-produce penicillin and today is the world's largest manufacturer and distributor of psychiatric medications.

Contents

[hide]

[edit] Company profile

 
Eli Lilly and Company's global headquarters, in Indianapolis, Indiana, United States
A Fortune 500 corporation, Eli Lilly had revenues of $20 billion in 2008, making it the 148th largest company in the United States and the 10th largest corporation by global pharmaceutical sales. The company is publicly traded on the New York Stock Exchange and is a member of the S&P 500 stock index. Eli Lilly was one of the Nifty Fifty stocks that propelled the mid 20th century bull market. Eli Lilly is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[2]

[edit] History

Colonel Eli Lilly, a pharmacist and a veteran of the American Civil War, began formulating plans to create a medical wholesale company while working in partnership at a drug store named Binford & Lilly. His wife's death from malaria a few years earlier influenced him to see a need working capital. His first innovation was gelatin-coating for pills and capsules. Following on his experience of low-quality medicines used in the Civil War, Lilly committed himself to producing only high-quality prescription drugs, in contrast to the common and often ineffective patent medicines of the day. His products, which worked as advertised and gained a reputation for quality, began to become popular in the city. In his first year of business, sales reached $4,470 and by 1879, they had grown to $48,000. He hired his brother, James, to take over sales in 1878. Other family members were also employed by the growing company, his cousin Evan Lilly was hired as a bookkeeper; his grandsons Eli and Josiah were hired to run errands and other odd jobs. In 1881 he formally incorporated the company, naming it Eli Lilly and Company. By the late 1880s he was one of the area's leading businessmen with over one-hundred employees and $200,000 in annual sales.[3]
 
An assortment of Lilly's throat lozenges from a 1906 sales book.
Eli Lilly and company was the first pharmaceutical company of its kind. At first Lilly was the company’s only researcher, but as his business grew, he created a laboratory and employed a department dedicated to creating new drugs. He hired his first scientist dedicated to research in 1886. Their methods of research were based on Lilly's. He also insisted on quality assurance, and instituted mechanisms to ensure that the drugs being produced worked as advertised, had the correct combination of ingredients, and that only the correct dosage of medicines was contained in each pill. He was aware of the addictive and dangerous nature of some of his drugs, and also pioneered the concept of only giving such drugs to people who had first seen a physician to determine if they needed the medicine.[4]
 
Colonel Eli Lilly (1838–1898), founder
Among the company's innovations was fruit flavoring for medicines and sugarcoated pills making their medicines easier to take.[5] His growing business led him to purchase additional facilities for research and production. He began to purchase a complex of buildings on McCarty Street in south Indianapolis, other businesses followed and the area began to develop into a major business area of the city. In 1890 he turned over his business to his son Josiah, who ran the company for the several decades. He focused his own free time on growing number of the civic organizations he was involved in, including the Charity Organization Society, the forerunner of the United Way.[3] The 1890s were a tumultuous decade economically, but the company was able to survive and came out stronger than ever.[6] In 1894 the company purchased a plant to be used solely for creating capsules. Several technological advances were achieved by the company, and the creation was automated. Over the next few years the company began to create tens of millions of capsules and pills annually.[7]
 
Josiah K. Lilly, Sr. (1861–1948), second company president.
When Eli Lilly died in 1898, his son Josiah K. Lilly, Sr. inherited the company. Josiah also continued his father's civic mindedness and ordered the company to send much needed medicine to support recovery efforts following the 1906 San Francisco earthquake. Josiah oversaw a large expansion of the company and advocated government regulation of medicines, leading to the passages of the Pure Food and Drug Law in 1906. In 1919, Josiah Lilly hired biochemist George Henry Alexander Clowes as director of biochemical research. Clowes' negotiations with researchers who developed insulin at the University of Toronto helped launch the first successful large-scale production of insulin in 1923. The success of insulin enabled the company to attract well-respected scientists and, with them, make more medical advances. Like his father, Josiah retired from the business and turned it over to his oldest son so he could take a more active role in philanthropy.
 
Eli Lilly (1885–1977), third company president.
Eli Lilly, the grandson of Col. Lilly, was named as the company's president in 1932 to succeed his father. In 1934, he led the company to make its first venture overseas when a Lilly office was opened in England. World War II brought production at Lilly to a new high with the manufacturing of Merthiolate and blood plasma. In 1943, the company began full-scale production of penicillin, the first company to mass produce the new medicine. Eli Lilly International Corp. was formed in 1943 as a subsidiary to encourage business trade abroad. In 1945, the company opened a new plant on South Kentucky Avenue in Indianapolis and, by 1948, Lilly employed nearly 7,000 people. The same year, Eli Lilly relinquished the presidency to his brother, Josiah K. Lilly, Jr. In 1952, Josiah, Jr. took the company public; the first public shares of stock were offered and, in 1953, Eugene N. Beesley was named the company's new president. He was the first non-family member to run the company. Lilly continued to expand. In 1950, Tippecanoe Laboratories, in Lafayette, Indiana, increased antibiotic production with its patent on erythromycin. In 1954, Elanco Products Co. was formed for the production of veterinary pharmaceuticals. In 1963, with an acquisition from Distillers Company, the company established a major factory in Liverpool. In 1968, Lilly Research Centre Ltd. near London, England was built. It was the company's first research facility outside the United States. In 1969, the company opened a new plant in Clinton, Indiana. Lilly made an uncharacteristic, but ultimately profitable, move in 1971 when it bought cosmetic manufacturer Elizabeth Arden for $38 million. Sixteen years later, Lilly sold Arden to Fabergé in 1987 for $657 million. Richard Wood was named CEO of Lilly in 1973. During the 1970s and 1980s, Eli Lilly and Company saw a flurry of drug production: antibiotic Keflex in 1971; heart drug Dobutrex in 1977; Ceclor, which would become the world's top selling oral antibiotic, in 1979; leukemia drug Eldisine; antiarthritic Oraflex; and analgesic Darvon. Lilly ventured into medical instruments through the acquisition of IVAC Corp., which manufactures vital signs and intravenous fluid infusion monitoring systems. Lilly also purchased Cardiac Pacemaker, a manufacturer of heart pacemakers. In 1989, a joint agri-chemical venture between Elanco Products Co. and Dow Chemical created DowElanco. In 1997, Lilly sold its 40 percent share in the company to Dow Chemical for $1.6 billion and the name was changed to Dow AgroSciences[8] In 1991, Vaughn Bryson was named CEO of Eli Lilly. During his 18-month tenure, the company reported its first quarterly loss ever. Randall L. Tobias, former vice-chairman of AT&T, was named Bryson's replacement in 1993. He was the first official recruited from outside of the company. Sidney Taurel, former chief operating officer of Lilly was named CEO in 1998, replacing Tobias. Taurel was named chairman in January 1999.
 
Eli Lilly's present day global manufacturing plants.
In 1998, Eli Lilly formed a joint venture with Icos Corporation (ICOS), a Bothell, Washington based biotechnology company, to develop and commercialize Cialis for the treatment of erectile dysfunction. In October 2006, Eli Lilly announced its intention to acquire Icos, for $2.1 billion, or $32 a share. The initial attempt to acquire Icos failed under pressure from large institutional shareholders, causing Lilly to offer $34 per share. ISS, a proxy advisory firm, advised Icos shareholders to reject the proposal as undervalued. However, the acquisition was approved by Icos shareholders and Eli Lilly completed its acquisition of the company on January 29, 2007. Since ICOS had no other products in development beyond Cialis, Eli Lilly promptly closed Icos operations and terminated nearly 500 Icos employees, except for 127 employees working at the biologics facility. In December 2007, CMC Biopharmaceuticals A/S (CMC), a Copenhagen, Denmark-based provider of contract biomanufacturing services, bought the Bothell-based biologics facility from Eli Lilly and retained the existing 127 employees. In January 2009, the largest criminal fine in U.S. history was imposed on Lilly for illegal marketing of its best-selling product, the atypical antipsychotic medication, Zyprexa. In January 2011, Boehringer Ingelheim and Eli Lilly and Company published their worldwide agreement for the concerted development and marketing of new APIs for diabetes therapy. Oral antidiabetika of Boehringer Ingelheim--Linagliptin and BI 10773, as well as two insulin analogs of Lilly – LY2605541 und LY2963016--are at present in phase II and III of clinical development.[9]

[edit] Collaborative research

In addition to internal research and development activities Eli Lilly is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[10][11] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[12]

[edit] Pharmaceutical brands

Among the company's major pharmaceutical breakthroughs are cephalosporin, erythromycin, insulin, and Prozac (fluoxetine), a selective serotonin reuptake inhibitor (SSRI) for the treatment of clinical depression. Among other distinctions, Lilly is the world's largest manufacturer and distributor of medications used in a broad range of psychiatric and mental health-related conditions, including clinical depression, generalized anxiety disorder, narcotic addiction, insomnia, bipolar disorder, schizophrenia, and others.

[edit] Cialis

Further information: Tadalafil
In 2003, Eli Lilly introduced Cialis (tadalafil), a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours, causing it sometimes to be dubbed the "weekend pill". Cialis was developed in a partnership with biotechnology company Icos Corporation. On December 18, 2006 Lilly bought Icos in order to gain full control of the product. With its television advertisement for Cialis during the 2004 Super Bowl Halftime Show, Eli Lilly was one of several companies whose costly 2004 Super Bowl Halftime advertisements were largely overshadowed by the Janet Jackson and Justin Timberlake Super Bowl XXXVIII halftime show controversy.

[edit] Cymbalta

Further information: Duloxetine
Another Lilly manufactured anti-depressant, Cymbalta, a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia and neuropathy.

[edit] Gemzar

Further information: Gemcitabine
In 1996, the U.S. Food and Drug Administration approved Gemzar for the treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer (usually in coordination with 5-FU chemotherapy and radiology). Gemzar also is routinely used in the treatment of non-small cell lung cancer.

[edit] Methadone

Further information: Methadone
Eli Lilly was the first distributor of methadone, an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

[edit] Prozac

Further information: Fluoxetine
Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide. Prozac has given rise to a number of comparably-functioning therapies for the treatment of clinical depression and other central nervous system disorders such as obsessive compulsive disorder, bulimia nervosa, and panic disorders.

[edit] Prozac in popular culture

Because of its wide appeal as a popular anti-depressant, Prozac has had numerous references to it in popular culture, including many books, movies, and songs. The autobiographical book Prozac Nation was authored in 1994 by Elizabeth Wurtzel; it was turned into a movie of the same name, Prozac Nation, in 2001, starring Christina Ricci. A 1993 book, Listening to Prozac, was a generally critical look at Prozac and its side effects. A 1994 book, Talking Back to Prozac, by psychiatrist Peter Breggin also focuses on Prozac side effects. Prozac is referenced by the rapper Jay-Z in the 1998 song "Nigga What, Nigga Who". In the HBO fictional series The Sopranos, Tony Soprano's use of Prozac is periodically referenced.

[edit] Secobarbital

Further information: Secobarbital
Eli Lilly has manufactured Secobarbital, a barbiturate derivative with anaesthetic, anticonvulsant, sedative and hypnotic properties. Lilly marketed Secobarbital under the brand name Seconal. Secobarbital is indicated for the treatment of epilepsy, temporary insomnia and as a pre-operative medication to produce anaesthesia and anxiolysis in short surgical, diagnostic, or therapeutic procedures which are minimally painful. With the onset of new therapies for the treatment of these conditions, Secobarbital has been less utilized, and Lilly ceased manufacturing it in 2001.

[edit] Secobarbital overdoses

Secobarbital gained considerable attention during the 1970s, when it gained popularity as a recreational drug. On September 18, 1970, rock guitarist legend Jimi Hendrix died from a secobarbital overdose. On June 22, 1969 secobarbital overdose was the cause of death of actress Judy Garland. The drug was a central part of the plot of the hugely popular novel Valley of the Dolls by Jacqueline Susann in which three highly successful Hollywood women each fall victim, in various ways, to the drug. The novel was later released as a film by the same name.

[edit] Thimerosal

Further information: Thiomersal
Eli Lilly has developed the vaccine preservative Thiomersal (also called Merthiolate and Thimerosal). Thiomersal is effective by causing susceptible bacteria to autolyze.

[edit] Additional Eli Lilly therapies

[edit] Personnel

A number of global leaders in the fields of health policy, management, and scientific research have worked at Lilly, including:
Prominent Lilly board members have included:

[edit] Accolades

In 2006, Fortune magazine named Eli Lilly and Company one of the top 100 companies in the United States for which to work. Also in 2006, Barron's Magazine named the company among the top 500 best managed companies in the U.S. The company was named one of the top 10 best companies for working mothers in 2004 by Working Mothers magazine.

[edit] Controversy

Eli Lilly has been involved in numerous controversies, including political and medical ethics controversies. Eli Lilly is now the sole manufacturer of BGH (having purchased the rights to manufacture the drug from Monsanto), the artificial hormone given to dairy cows that may increase people’s risk of cancer.

[edit] Lawsuits

Further information: Standard Gravure shooting
In one of three cases to ever go to trial for SSRI indication in suicide, a Kentucky man, Joseph Wesbecker, who had been on Prozac, went to his workplace and opened fire, killing seven people and injuring 12 others before turning the gun on himself. The jury returned a 9-to-3 verdict in favor of Lilly. The case's judge, however, took the matter to the Kentucky Supreme Court, which found that "there was a serious lack of candor with the trial court and there may have been deception, bad faith conduct, abuse of judicial process and, perhaps even fraud." The judge later revoked the verdict and instead recorded the case as settled. The value of the secret settlement deal has never been disclosed. In June 2008, Eli Lilly and Company agreed to settle a lawsuit stemming from discrimination charges. The lawsuit alleged that the company withheld severance pay in order to convince a former employee, Starr E. Johnson, to withdraw her lawsuit. Eli Lilly was accused by the U.S. Equal Employment Opportunity Commission of violating the federal anti-discrimination law when they withheld severance benefits to Johnson. Johnson originally filed a discrimination charge after she was fired in 2005. She is a black woman and became disfigured in 1997 when she was exposed to a blood pathogen. Her charge claimed that her supervisor stated that he was put in charge "so that he could watch her and get rid of her and that no one liked looking at her." Eli Lilly was ordered to pay $54,400 in severance pay, $7,000 in interest and compensatory damages, along with $3,000 in attorney fees.[13]

[edit] Criminal prosecution

Eli Lilly pleaded guilty to violating U.S. law in its marketing of its anti-psychotic drug Zyprexa and was ordered to pay $1.42 billion to settle criminal and civil allegations. Eli Lilly said it had entered a misdemeanor plea for violation of federal law in its off-label promotion of Zyprexa between September 1999 and March 2001 and agreed to pay $615 million. The U.S. Justice Department said the criminal fine of $515 million was the largest ever in a health care case, and the largest criminal fine for an individual corporation ever imposed in a U.S. criminal prosecution of any kind. Lilly also agreed to forfeit $100 million in the settlement. However, the company is still pursuing legal action against the lawyer, James Gottstein, who helped publicize the issues by passing documents to The New York Times and other media outlets.

[edit] See also

[edit] References

  1. ^ a b c d e f "2010 Form 10-K, Eli Lilly and Company". United States Securities and Exchange Commission.
  2. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). pp. 49. Retrieved 2008-08-25.
  3. ^ a b Bodenhamer, p. 911
  4. ^ "Milestones in Medical Research". Eli Lilly & co.. Retrieved 2009-04-07.
  5. ^ Price, p. 59
  6. ^ Price, p. 60
  7. ^ Podczeck, p. 12–13
  8. ^ http://www.dowagro.com/newsroom/mediakit/facts.htm
  9. ^ Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide
  10. ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
  11. ^ "InnoMed PredTox Member Organizations". Retrieved 2008-08-25.
  12. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25.[dead link]
  13. ^ Murphy, Tom (2008-06-30). ""Lilly agrees to settle discrimination lawsuit"". Chicago Tribune. Retrieved 2008-07-01.

[edit] Further references

  • Bodenhamer, David J. (1994). The Encyclopedia of Indianapolis. Indiana University Press. ISBN 0253312221.
  • Price, Nelson (1997). Indiana Legends. Emmis Books. ISBN 1578600065.
  • Podczeck, Fridrun & Jones, Brian E (2004). Pharmaceutical capsules. Pharmaceutical Press. ISBN 0853695687.

[edit] External links

[show]v · d · eEli Lilly and Company
[show]v · d · ePharmaceutical companies of the United States
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)